bioAffinity Technologies, Inc. released a case study on March 26, 2025, highlighting CyPath® Lung's role in detecting a second primary lung cancer. The patient, a 72-year-old with a history of non-small cell lung cancer, was under surveillance when CT scans showed changes in scar tissue.
Traditional diagnostic approaches were challenging due to contraindications for serum markers and potential inconclusiveness of PET scans on smaller nodules. However, the CyPath® Lung result indicated 'likely cancer,' prompting a PET scan and bronchoscopy.
This led to the confirmation of a distinct small cell carcinoma, enabling timely and appropriate treatment. The case demonstrates CyPath® Lung's ability to provide pivotal real-time information for early and accurate detection, particularly in patients with a history of lung cancer, which can improve patient outcomes and potentially lower healthcare costs.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.